Analyst Price Targets — OFIX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 11:12 am | — | Stifel Nicolaus | $18.00 | $12.46 | TheFly | Orthofix price target lowered to $18 from $22 at Stifel |
| November 5, 2025 2:21 pm | Michael Petusky | Barrington | $18.00 | $14.81 | TheFly | Orthofix price target raised to $18 from $17 at Barrington |
| October 28, 2025 10:51 am | — | Stifel Nicolaus | $22.00 | $16.12 | TheFly | Orthofix resumed with a Buy at Stifel |
| November 8, 2024 8:01 am | Mathew Blackman | Stifel Nicolaus | $24.00 | $18.22 | StreetInsider | Stifel Upgrades Orthofix International (OFIX) to Buy |
| June 28, 2022 1:47 pm | Mathew Blackman | Stifel Nicolaus | $31.00 | $24.12 | TheFly | Stifel cuts Orthofix target, says momentum 'faded' during Q2 |
Latest News for OFIX
NEW YORK and NEW ORLEANS, April 17, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Vasamed (OTCMKTS:VSMD - Get Free Report) and Orthofix Medical (NASDAQ: OFIX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability. Earnings and Valuation This table compares Vasamed and Orthofix
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NasdaqGS: OFIX). On September 12, 2023, the Company announced the appointment of an interim CEO, interim CFO, and interim CLO, effective…
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine…
JPMorgan Chase and Co. lifted its stake in shares of Orthofix Medical Inc. (NASDAQ: OFIX) by 33.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 258,035 shares of the medical device company's stock after acquiring an additional 64,486 shares during the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OFIX.
U.S. House Trading
No House trades found for OFIX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.